| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 142, 1689-1694, Copyright © 1993 by American Society for Investigative Pathology
REGULAR ARTICLES |
H Kreipe, HH Wacker, HJ Heidebrecht, K Haas, M Hauberg, M Tiemann and R Parwaresch
Institute of Pathology and Hematopathology, University of Kiel, Germany.
Relevant prognostic information can be added to the histological classification of non-Hodgkin's lymphoma (NHL) by the determination of the growth fraction. In unfixed fresh tissue samples the Ki-67 antigen has proven its utility as an operational marker of proliferative activity in NHL. We have generated a monoclonal antibody directed against a formalin-resistant epitope of the Ki-67 antigen, designated Ki-S5. The immunoreactivity of Ki-S5 is confined to the nuclei of proliferating cells and, unlike Ki-67, no cross-reactivity with cytoplasmic antigens of epithelial cells occurs. In 100 cases of different NHL types, parallel staining of Ki-67 and Ki-S5 antigen yielded almost identical results in fresh tissues and fixed tissues, respectively (P < 0.00001; r = 0.95). In some cases, the Ki-S5 labeling index exceeded that of Ki-67, most probably due to a partial degradation of the epitope recognized by Ki-67 in frozen stored tissue samples. Significant differences in the median Ki-S5 labeling index could be demonstrated between high grade (> 50%) and low grade malignant NHL (< or = 30%), although the proliferative activity varied to a considerable range within identical histological categories (P < 0.001). We conclude that Ki-S5 provides a reliable means to assess proliferation in paraffin-embedded NHL specimens. Retrospective studies relating the proliferative activity to clinical outcome are thus rendered possible using archival routinely processed tissue samples.
This article has been cited by other articles:
 |
|
 |
|
  M. Anlauf, M. K.-H. Schafer, T. Schwark, N. von Wurmb-Schwark, V. Brand, B. Sipos, H.-P. Horny, R. Parwaresch, W. Hartschuh, L. E. Eiden, et al. Vesicular Monoamine Transporter 2 (VMAT2) Expression in Hematopoietic Cells and in Patients with Systemic Mastocytosis J. Histochem. Cytochem., February 1, 2006; 54(2): 201 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hoffmann, M. Tiemann, C. Schrader, D. Janssen, E. Wolf, M. Vierbuchen, R. Parwaresch, K. Ernestus, A. Plettenberg, A. Stoehr, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping Blood, September 1, 2005; 106(5): 1762 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rudolph, P. Alm, H.-J. Heidebrecht, H. Bolte, V. Ratjen, B. Baldetorp, M. Ferno, H. Olsson, and R. Parwaresch Immunologic Proliferation Marker Ki-S2 as Prognostic Indicator for Lymph Node-Negative Breast Cancer J Natl Cancer Inst, February 3, 1999; 91(3): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Ott, J. Bartkova, J. Bartek, A. Durr, L. Fischer, G. Ott, H. K. Muller-Hermelink, and H. Kreipe Cyclin D1 Expression in Mantle Cell Lymphoma Is Accompanied by Downregulation of Cyclin D3 and Is Not Related to the Proliferative Activity Blood, October 15, 1997; 90(8): 3154 - 3159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.J. Heidebrecht, F. Buck, J. Steinmann, R. Sprenger, H.H. Wacker, and R. Parwaresch p100: A Novel Proliferation-Associated Nuclear Protein Specifically Restricted to Cell Cycle Phases S, G2 , and M Blood, July 1, 1997; 90(1): 226 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ott, J. Kalla, M. M. Ott, B. Schryen, T. Katzenberger, J. G. Muller, and H. K. Muller-Hermelink Blastoid Variants of Mantle Cell Lymphoma: Frequent bcl-1 Rearrangements at the Major Translocation Cluster Region and Tetraploid Chromosome Clones Blood, February 15, 1997; 89(4): 1421 - 1429. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
